BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
benzinga_article
BeyondSpring shares are trading higher after its subsidiary SEED Therapeutics secured FDA Orphan Drug Designation for Neuroblastoma candidate ST‑01156.
